1932

Abstract

Recent dietary reference intake workshops focusing on nutrient requirements in chronic disease populations have called attention to the potential adverse effects of chronic medication use on micronutrient status. Although this topic is mostly ill defined in the literature, several noteworthy drug–nutrient interactions (DNIs) are of clinical and public health significance. The purpose of this narrative review is to showcase classic examples of DNIs and their impact on micronutrient status, including those related to antidiabetic, anticoagulant, antihypertensive, antirheumatic, and gastric acid–suppressing medications. Purported DNIs related to other drug families, while relevant and worthy of discussion, are not included. Unlike previous publications, this review is primarily focused on DNIs that have sufficient evidence supporting their inclusion in US Food and Drug Administration labeling materials and/or professional guidelines. While the evidence is compelling, more high-quality research is needed to establish clear and quantitative relationships between chronic medication use and micronutrient status.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-nutr-120420-023854
2021-10-11
2024-06-22
Loading full text...

Full text loading...

/deliver/fulltext/nutr/41/1/annurev-nutr-120420-023854.html?itemId=/content/journals/10.1146/annurev-nutr-120420-023854&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. 2012. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:2 Supple44S–88S
    [Google Scholar]
  2. 2. 
    Am. Coll. Rheumatol 2020. 2020 American College of Rheumatology Guideline for the Management of Rheumatoid Arthritis Clin. Pract. Guidel., Am. Coll. Rheumatol Atlanta: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Rheumatoid-Arthritis
    [Google Scholar]
  3. 3. 
    Am. Diabetes Assoc 2019. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care 42:Suppl. 1S90–90
    [Google Scholar]
  4. 4. 
    Am. Diabetes Assoc 2020. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 43:Suppl. 1S98–98
    [Google Scholar]
  5. 5. 
    Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM et al. 2016. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J. Clin. Endocrinol. Metab. 101:41754–61
    [Google Scholar]
  6. 6. 
    Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG et al. 2015. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment. Pharmacol. Ther. 41:111162–74
    [Google Scholar]
  7. 7. 
    Aung K, Htay T. 2011. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst. Rev. 10:CD005185
    [Google Scholar]
  8. 8. 
    Baber U, Mastoris I, Mehran R. 2014. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat. Rev. Cardiol. 11:693–703
    [Google Scholar]
  9. 9. 
    Bauer UE, Briss PA, Goodman RA, Bowman BA. 2014. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet 384:993745–52
    [Google Scholar]
  10. 10. 
    Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. 2000. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23:91227–31
    [Google Scholar]
  11. 11. 
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L et al. 2008. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358:1887–98
    [Google Scholar]
  12. 12. 
    Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR. 2007. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos. Int. 18:4479–86
    [Google Scholar]
  13. 13. 
    Boonyawat K, Wang L, Lazo-Langner A, Kovacs MJ, Yeo E et al. 2016. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin: a randomised trial. Thromb. Haemost. 116:3480–85
    [Google Scholar]
  14. 14. 
    Booth SL. 2010. Dietary vitamin K guidance: an effective strategy for stable control of oral anticoagulation. Nutr. Rev. 68:3178–81
    [Google Scholar]
  15. 15. 
    Boullata JI. 2019. Drug-nutrition interactions and the brain: It's not all in your head. Curr. Nutr. Rep. 8:92–98
    [Google Scholar]
  16. 16. 
    Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G et al. 2001. Principal results from the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Eur. Heart J. Suppl 3:B20–20
    [Google Scholar]
  17. 17. 
    Buttorff C, Ruder T, Bauman M. 2017. Multiple Chronic Conditions in the United States Santa Monica, CA: RAND Corp.
    [Google Scholar]
  18. 18. 
    Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O'Fallon WM et al. 1999. Long-term use of oral anticoagulants and the risk of fracture. Arch. Intern. Med. 159:151750–56
    [Google Scholar]
  19. 19. 
    Chan LN. 2013. Drug-nutrient interactions. J. Parenter. Enter. Nutr. 37:4450–59
    [Google Scholar]
  20. 20. 
    Chapman LE, Darling AL, Brown JE. 2016. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 42:5316–27
    [Google Scholar]
  21. 21. 
    Charkos TG, Liu Y, Jin L, Yang S 2019. Thiazide use and fracture risk: an updated Bayesian meta-analysis. Sci. Rep. 9:19754
    [Google Scholar]
  22. 22. 
    Chen A, Stecker E, Warden BA 2020. Direct oral anticoagulant use: a practical guide to common clinical challenges. J. Am. Heart Assoc. 9:13e017559
    [Google Scholar]
  23. 23. 
    Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ et al. 2015. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren. Fail. 37:71237–41
    [Google Scholar]
  24. 24. 
    Corley DA, Kubo A, Zhao W, Quesenberry C. 2010. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:193–101
    [Google Scholar]
  25. 25. 
    Cronstein BN, Aune TM. 2020. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat. Rev. Rheumatol. 16:145–54
    [Google Scholar]
  26. 26. 
    De Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE. 2009. Improved oral anticoagulation after a dietary vitamin K–guided strategy: a randomized controlled trial. Circulation 120:121115–22
    [Google Scholar]
  27. 27. 
    de Denus S, Tardif JC, White M, Bourassa MG, Racine N et al. 2006. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am. Heart J. 152:4705–12
    [Google Scholar]
  28. 28. 
    De Jager J, Kooy A, Lehert P, Wulffelé MG, Van Der Kolk J et al. 2010. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 340:c2181
    [Google Scholar]
  29. 29. 
    DeFronzo RA, Goodman AMMulticent. Metformin Study Group 1995. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:541–49
    [Google Scholar]
  30. 30. 
    den Elzen WPJ, Groeneveld Y, De Ruijter W, Souverijn JHM, Le Cessie S et al. 2008. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment. Pharmacol. Ther. 27:6491–97
    [Google Scholar]
  31. 31. 
    Desai AS, Swedberg K, McMurray JJV, Granger CB, Yusuf S et al. 2007. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J. Am. Coll. Cardiol. 50:201959–66
    [Google Scholar]
  32. 32. 
    Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N et al. 2013. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann. Intern. Med. 158:6447–55
    [Google Scholar]
  33. 33. 
    Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. 2008. Do acid-lowering agents affect vitamin B12 status in older adults?. J. Am. Med. Dir. Assoc. 9:3162–67
    [Google Scholar]
  34. 34. 
    Emken BEG, Lundell LR, Wallin L, Myrvold HE, Engström C et al. 2017. Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years. Scand. J. Gastroenterol. 52:111–17
    [Google Scholar]
  35. 35. 
    Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK et al. 2019. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42:5731–54
    [Google Scholar]
  36. 36. 
    Fisher MC, Cronstein BN. 2009. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36:3539–45
    [Google Scholar]
  37. 37. 
    Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. 2000. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35:51025–30
    [Google Scholar]
  38. 38. 
    Freedberg DE, Kim LS, Yang YX. 2017. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152:4706–15
    [Google Scholar]
  39. 39. 
    Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M et al. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:232981–97
    [Google Scholar]
  40. 40. 
    Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. 2006. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch. Intern. Med. 166:2241–46
    [Google Scholar]
  41. 41. 
    Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R et al. 2011. Laparoscopic antireflux surgery versus esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 305:191969–77
    [Google Scholar]
  42. 42. 
    Gebuis EPA, Rosendaal FR, van Meegen E, van der Meer FJM. 2011. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica 96:4583–89
    [Google Scholar]
  43. 43. 
    Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL et al. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:9386772–76
    [Google Scholar]
  44. 44. 
    Gray SL, Lacroix AZ, Larson J, Robbins J, Cauley JA et al. 2010. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch. Intern. Med. 170:9765–71
    [Google Scholar]
  45. 45. 
    Green R. 2011. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am. J. Clin. Nutr. 94:252–63
    [Google Scholar]
  46. 46. 
    Green R, Allen LH, Bjørke-Monsen AL, Brito A, Guéant JL et al. 2017. Vitamin B12 deficiency. Nat. Rev. Dis. Primers 3:17040
    [Google Scholar]
  47. 47. 
    Gu ZC, Zhou LY, Shen L, Zhang C, Pu J et al. 2018. Non-vitamin K antagonist oral anticoagulants versus warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 9:348
    [Google Scholar]
  48. 48. 
    Hales CM, Servais J, Martin CB, Kohen D. 2019. Prescription drug use among adults aged 40–79 in the United States and Canada NCHS Data Brief 347 Natl. Cent. Health Stat Hyattsville, MD:
    [Google Scholar]
  49. 49. 
    Harrington DJ. 2017. Laboratory assessment of vitamin B12 status. J. Clin. Pathol. 70:2168–73
    [Google Scholar]
  50. 50. 
    Hess MW, De Baaij JHF, Broekman MMTJ, Bisseling TM, Haarhuis BJT et al. 2017. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study. Pharmacogenet. Genom. 27:383–88
    [Google Scholar]
  51. 51. 
    Hripcsak G, Suchard MA, Shea S, Chen R, You SC et al. 2020. Comparison of cardiovascular and safety outcomes of chlorthalidone versus hydrochlorothiazide to treat hypertension. JAMA Intern. Med. 180:4542–51
    [Google Scholar]
  52. 52. 
    Huang HK, Liu PPS, Hsu JY, Lin SM, Peng CCH et al. 2020. Risk of osteoporosis in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants or warfarin. J. Am. Heart Assoc. 9:2e013845
    [Google Scholar]
  53. 53. 
    Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. 1998. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 279:9657–62
    [Google Scholar]
  54. 54. 
    Jamal SA, Browner WS, Bauer DC, Cummings SR. 1998. Warfarin use and risk for osteoporosis in elderly women. Ann. Intern. Med. 128:10829–32
    [Google Scholar]
  55. 55. 
    January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE et al. 2019. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 140:2e125–125
    [Google Scholar]
  56. 56. 
    Johnson JA. 2013. Pharmacogenetics in clinical practice: How far have we come and where are we going?. Pharmacogenomics 14:7835–43
    [Google Scholar]
  57. 57. 
    Kancherla V, Garn JV, Zakai NA, Williamson RS, Cashion WT et al. 2016. Multivitamin use and serum vitamin B12 concentrations in older-adult metformin users in REGARDS. 2003–2007 PLOS ONE 11:82003–7
    [Google Scholar]
  58. 58. 
    Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. 2015. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314:171818–31
    [Google Scholar]
  59. 59. 
    Kent PD, Luthra HS, Michet CJ. 2004. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J. Rheumatol. 31:91727–31
    [Google Scholar]
  60. 60. 
    Kooy A, De Jager J, Lehert P, Bets D, Wulffelé MG et al. 2009. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169:6616–25
    [Google Scholar]
  61. 61. 
    LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. 2000. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 133:7516–26
    [Google Scholar]
  62. 62. 
    Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. 2000. Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther. 14:6651–68
    [Google Scholar]
  63. 63. 
    Lam JR, Schneider JL, Quesenberry CP, Corley DA. 2017. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology 152:4821–29.e1
    [Google Scholar]
  64. 64. 
    Lam JR, Schneider JL, Zhao W, Corley DA. 2013. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:222435–42
    [Google Scholar]
  65. 65. 
    Lau WCY, Chan EW, Cheung CL, Sing CW, Man KKC et al. 2017. Association between dabigatran versus warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA 317:111151–58
    [Google Scholar]
  66. 66. 
    Leblanc C, Dubé MP, Presse N, Dumas S, Nguyen M et al. 2016. Avoidance of vitamin K-rich foods is common among warfarin users and translates into lower usual vitamin K intakes. J. Acad. Nutr. Diet. 116:61000–7
    [Google Scholar]
  67. 67. 
    Lee TC, McDonald EG. 2020. Deprescribing proton pump inhibitors: overcoming resistance. JAMA Intern. Med. 180:4571–73
    [Google Scholar]
  68. 68. 
    Leroith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B et al. 2019. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 104:1520–74
    [Google Scholar]
  69. 69. 
    Liao S, Gan L, Mei Z. 2019. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: an updated systematic review and meta-analysis. Medicine 98:13e15011
    [Google Scholar]
  70. 70. 
    Liu Q, Li S, Quan H, Li J. 2014. Vitamin B12 status in metformin treated patients: systematic review. PLOS ONE 9:68–13
    [Google Scholar]
  71. 71. 
    Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ et al. 2020. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern. Med. 180:2245–53
    [Google Scholar]
  72. 72. 
    MacFarlane AJ, Cogswell ME, De Jesus JM, Greene-Finestone LS, Klurfeld DM et al. 2019. A report of activities related to the Dietary Reference Intakes from the Joint Canada-US Dietary Reference Intakes Working Group. Am. J. Clin. Nutr. 109:2251–59
    [Google Scholar]
  73. 73. 
    Mahtani KR, Heneghan CJ, Nunan D, Roberts NW. 2014. Vitamin K for improved anticoagulation control in patients receiving warfarin. Cochrane Database Syst. Rev. 5:CD009917
    [Google Scholar]
  74. 74. 
    Massie BM, Armstrong PW, Cleland JGF, Horowitz JD, Packer M et al. 2001. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Arch. Intern. Med. 161:2165–71
    [Google Scholar]
  75. 75. 
    McColl KEL. 2009. Effect of proton pump inhibitors on vitamins and iron. Am. J. Gastroenterol. 104:S5–5
    [Google Scholar]
  76. 76. 
    Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L et al. 2019. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 157:3682–91.e2
    [Google Scholar]
  77. 77. 
    Mohn ES, Kern HJ, Saltzman E, Mitmesser SH, McKay DL. 2018. Evidence of drug-nutrient interactions with chronic use of commonly prescribed medications: an update. Pharmaceutics 10:136
    [Google Scholar]
  78. 78. 
    Nathan DM, Barrett-Connor E, Crandall JP, Edelstein SL, Goldberg RB et al. 2015. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3:11866–75
    [Google Scholar]
  79. 79. 
    Natl. Acad. Sci. Eng. Med 2017. Guiding Principles for Developing Dietary Reference Intakes Based on Chronic Disease Washington, DC: Natl. Acad. Press
    [Google Scholar]
  80. 80. 
    Natl. Acad. Sci. Eng. Med 2018. Examining Special Nutritional Requirements in Disease States Washington, DC: Natl. Acad. Press
    [Google Scholar]
  81. 81. 
    Natl. Acad. Sci. Eng. Med 2019. Consensus Study Report Highlights Dietary Reference Intakes for Sodium and Potassium Washington, DC: Natl. Acad. Press
    [Google Scholar]
  82. 82. 
    Natl. Cent. Chronic Dis. Prev. Health Promot 2019. Chronic diseases in America. Centers for Disease Control and Prevention http://www.cdc.gov/chronicdisease
    [Google Scholar]
  83. 83. 
    Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. 2011. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 106:71209–18
    [Google Scholar]
  84. 84. 
    Ott SM, LaCroix AZ, Scholes D, Ichikawa LE, Wu K. 2008. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos. Int. 19:91315–22
    [Google Scholar]
  85. 85. 
    Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. 2018. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3 year trial. J. Diabetes Complicat. 32:2171–78
    [Google Scholar]
  86. 86. 
    Park CH, Kim EH, Roh YH, Kim HY, Lee SK. 2014. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLOS ONE 9:11e112558
    [Google Scholar]
  87. 87. 
    Penning-van Beest FJA, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BHC. 2002. Lifestyle and diet as risk factors for overanticoagulation. J. Clin. Epidemiol. 55:4411–17
    [Google Scholar]
  88. 88. 
    Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. 2012. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59:61104–9
    [Google Scholar]
  89. 89. 
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. 2007. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch. Intern. Med. 167:181930–36
    [Google Scholar]
  90. 90. 
    Pignatelli P, Pastori D, Vicario T, Bucci T, Del Ben M et al. 2015. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. Europace 17:81223–28
    [Google Scholar]
  91. 91. 
    Poly TN, Islam MM, Yang HC, Wu CC, Li YCJ. 2019. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos. Int. 30:103–14
    [Google Scholar]
  92. 92. 
    Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M et al. 2003. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289:192534–44
    [Google Scholar]
  93. 93. 
    Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC et al. 2017. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern. Med. 177:167–76
    [Google Scholar]
  94. 94. 
    Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. 2016. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 versus 2011. JAMA Intern. Med. 176:4473–82
    [Google Scholar]
  95. 95. 
    Ramos-Lopez O, Milagro FI, Allayee H, Chmurzynska A, Choi MS et al. 2017. Guide for current nutrigenetic, nutrigenomic, and nutriepigenetic approaches for precision nutrition involving the prevention and management of chronic diseases associated with obesity. J. Nutrigenet. Nutrigenom. 10:43–62
    [Google Scholar]
  96. 96. 
    Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM et al. 2000. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am. J. Med. 109:5362–70
    [Google Scholar]
  97. 97. 
    Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP. 2012. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999–2006. Diabetes Care 35:2327–33
    [Google Scholar]
  98. 98. 
    Rombouts EK, Rosendaal FR, van der Meer FJM. 2007. Daily vitamin K supplementation improves anticoagulant stability. J. Thromb. Haemost. 5:102043–48
    [Google Scholar]
  99. 99. 
    Sagar M, Janczewska I, Ljungdahl Å, Bertilsson L, Seensalu R. 1999. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment. Pharmacol. Ther. 13:4453–58
    [Google Scholar]
  100. 100. 
    Saito R, Takeda K, Yamamoto K, Nakagawa A, Aoki H et al. 2014. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. J. Thromb. Thrombolysis 38:105–14
    [Google Scholar]
  101. 101. 
    Samaras D, Samaras N, Lang PO, Genton L, Frangos E, Pichard C. 2013. Effects of widely used drugs on micronutrients: a story rarely told. Nutrition 29:4605–10
    [Google Scholar]
  102. 102. 
    Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB et al. 1998. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch. Intern. Med. 158:7741–51
    [Google Scholar]
  103. 103. 
    Sconce E, Avery P, Wynne H, Kamali F. 2007. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109:62419–23
    [Google Scholar]
  104. 104. 
    Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W et al. 2013. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 5:CD000951
    [Google Scholar]
  105. 105. 
    Shearer MJ, Newman P. 2008. Metabolism and cell biology of vitamin K. Thromb. Haemost. 100:4530–47
    [Google Scholar]
  106. 106. 
    Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR et al. 2016. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 68:1126
    [Google Scholar]
  107. 107. 
    Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M et al. 2016. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75:13–15
    [Google Scholar]
  108. 108. 
    Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C et al. 2020. Adverse effects of low-dose methotrexate: a randomized trial. Ann. Intern. Med. 172:6369–80
    [Google Scholar]
  109. 109. 
    Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S et al. 2019. Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies. Medicine 98:44e17788
    [Google Scholar]
  110. 110. 
    Stergiopoulos K, Brown DL. 2014. Genotype-guided versus clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern. Med. 174:81330–38
    [Google Scholar]
  111. 111. 
    Ting RZW, Szeto CC, Chan MHM, Ma KK, Chow KM. 2006. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch. Intern. Med. 166:181975–79
    [Google Scholar]
  112. 112. 
    Tran-Duy A, Connell NJ, Vanmolkot FH, Souverein PC, de Wit NJ et al. 2019. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study. J. Intern. Med. 285:2205–14
    [Google Scholar]
  113. 113. 
    Vaezi MF, Yang YX, Howden CW. 2017. Complications of proton pump inhibitor therapy. Gastroenterology 153:135–48
    [Google Scholar]
  114. 114. 
    Van Ede AE, Laan RFJM, Rood MJ, Huizinga TWJ, Van De Laar MAFJ et al. 2001. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:71515–24
    [Google Scholar]
  115. 115. 
    Violi F, Lip GYH, Pignatelli P, Pastori D. 2016. Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists: Is it really true? A systematic review. Medicine 95:10e2895
    [Google Scholar]
  116. 116. 
    Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C et al. 2009. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68:71086–93
    [Google Scholar]
  117. 117. 
    Wang J, Su K, Sang W, Li L, Ma S 2019. Thiazide diuretics and the incidence of osteoporotic fracture: a systematic review and meta-analysis of cohort studies. Front. Pharmacol. 10:1364
    [Google Scholar]
  118. 118. 
    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ et al. 2018. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:61269–324 Erratum. 2018 Hypertension 71(6):e136–39. Erratum. 2018. Hypertension 72(3):e33
    [Google Scholar]
  119. 119. 
    Whittle SL, Hughes RA. 2004. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 43:3267–71
    [Google Scholar]
  120. 120. 
    Wile DJ, Toth C. 2010. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 33:1156–61
    [Google Scholar]
  121. 121. 
    Wright J, Musini V, Gill R. 2018. First-line drugs for hypertension. Cochrane Database Syst. Rev. 4:CD001841
    [Google Scholar]
  122. 122. 
    Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC et al. 2003. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 254:5455–63
    [Google Scholar]
  123. 123. 
    Ye X, Liu H, Wu C, Qin Y, Zang J et al. 2011. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 23:9794–800
    [Google Scholar]
  124. 124. 
    Yetley EA, MacFarlane AJ, Greene-Finestone LS, Garza C, Ard JD et al. 2017. Options for basing Dietary Reference Intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working group. Am. J. Clin. Nutr. 105:1249S–85S
    [Google Scholar]
  125. 125. 
    Yu EW, Bauer SR, Bain PA, Bauer DC. 2011. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am. J. Med. 124:6519–26
    [Google Scholar]
  126. 126. 
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P et al. 2003. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:9386777–81
    [Google Scholar]
  127. 127. 
    Zdilla MJ. 2015. Metformin with either histamine H2-receptor antagonists or proton pump inhibitors: a polypharmacy recipe for neuropathy via vitamin B12 depletion. Clin. Diabetes 33:290–95
    [Google Scholar]
  128. 128. 
    Zhou B, Huang Y, Li H, Sun W, Liu J. 2016. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos. Int. 27:1339–47
    [Google Scholar]
  129. 129. 
    Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. 2018. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy 38:9907–20
    [Google Scholar]
/content/journals/10.1146/annurev-nutr-120420-023854
Loading
/content/journals/10.1146/annurev-nutr-120420-023854
Loading

Data & Media loading...

Supplementary Data

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error